Humana (NYSE:HUM) Price Target Cut to $360.00 by Analysts at Cantor Fitzgerald

Humana (NYSE:HUM) had its price target lowered by Cantor Fitzgerald from $391.00 to $360.00 in a report published on Thursday, Benzinga reports. The firm currently has a neutral rating on the insurance provider’s stock. Cantor Fitzgerald also issued estimates for Humana’s FY2024 earnings at $16.04 EPS.

Several other equities research analysts also recently weighed in on HUM. Truist Financial reissued a hold rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. Oppenheimer decreased their price objective on Humana from $415.00 to $370.00 and set an outperform rating for the company in a report on Thursday. Barclays decreased their price objective on Humana from $356.00 to $310.00 and set an equal weight rating for the company in a report on Tuesday, April 2nd. StockNews.com downgraded Humana from a strong-buy rating to a hold rating in a report on Friday, January 26th. Finally, Raymond James started coverage on Humana in a report on Friday, March 22nd. They issued a market perform rating for the company. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Humana has an average rating of Hold and an average price target of $424.50.

Humana Stock Performance

Shares of Humana stock opened at $305.90 on Thursday. The firm has a market capitalization of $36.86 billion, a P/E ratio of 19.05, a P/E/G ratio of 1.79 and a beta of 0.45. Humana has a 52 week low of $299.23 and a 52 week high of $541.21. The company has a quick ratio of 1.59, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average is $327.77 and its two-hundred day moving average is $393.91.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, beating the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm’s revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the firm posted $9.38 earnings per share. Research analysts forecast that Humana will post 16.08 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is 22.04%.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was purchased at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the transaction, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Rakuten Securities Inc. purchased a new position in shares of Humana in the fourth quarter valued at $25,000. Gradient Investments LLC boosted its stake in Humana by 200.0% in the 4th quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares during the last quarter. Cetera Trust Company N.A acquired a new stake in Humana in the 4th quarter worth about $28,000. Private Wealth Management Group LLC acquired a new stake in Humana in the 4th quarter worth about $32,000. Finally, Nvwm LLC boosted its stake in Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock worth $42,000 after buying an additional 25 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.